ALZAMEND NEURO, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
ALZAMEND NEURO, INC. (ALZN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $1.62 million for the 12-month period ending 2026-04-30, per its 10-K filed 2026-07-22.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2026-07-22
- ALZAMEND NEURO, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2026 was $1.62M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2026-04-30 | $1.62M 10-K · filed 2026-07-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |